

MAGEA1 Antibody (Center)

Purified Rabbit Polyclonal Antibody (Pab)

Catalog # AP6163a

Product Information

Application	WB, IHC-P, E
Primary Accession	P43355
Other Accession	NP_004979
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Clone Names	RB2081-2082
Calculated MW	34342
Antigen Region	143-173

Additional Information

Gene ID	4100
Other Names	Melanoma-associated antigen 1, Antigen MZ2-E, Cancer/testis antigen 11, CT11, MAGE-1 antigen, MAGEA1, MAGE1, MAGE1A
Target/Specificity	This MAGEA1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 143-173 amino acids from the Central region of human MAGEA1.
Dilution	WB~~1:1000 IHC-P~~1:100~500 E~~Use at an assay dependent concentration.
Format	Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	MAGEA1 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	MAGEA1
Synonyms	MAGE1, MAGE1A
Function	May be involved in transcriptional regulation through interaction with SNW1

and recruiting histone deacetylase HDAC1. May inhibit notch intracellular domain (NICD) transactivation. May play a role in embryonal development and tumor transformation or aspects of tumor progression. Antigen recognized on a melanoma by autologous cytolytic T-lymphocytes.

Cellular Location

Cytoplasm. Nucleus.

Tissue Location

Expressed in many tumors of several types, such as melanoma, head and neck squamous cell carcinoma, lung carcinoma and breast carcinoma, but not in normal tissues except for testes. Never expressed in kidney tumors, leukemias and lymphomas


Background

MAGEA1 is a member of the MAGEA gene family. The members of this family have their entire coding sequences located in the last exon, and the encoded proteins show 50 to 80% sequence identity between each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are expressed at a high level in a number of tumors of various histologic types, and are silent in normal tissues with the exception of testis and placenta. The MAGEA genes are clustered on chromosome Xq28. They may be implicated in some hereditary disorders, such as dyskeratosis congenita.

References



Suyama, T., et al., Leuk. Res. 26(12):1113-1118 (2002).
Mallon, A.M., et al., Genome Res. 10(6):758-775 (2000).
Rogner, U.C., et al., Genomics 29(3):725-731 (1995).
Schultz-Thater, E., et al., Int. J. Cancer 59(3):435-439 (1994).
Celis, E., et al., Mol. Immunol. 31(18):1423-1430 (1994).

Images



Western blot analysis of anti-MAGEA1 Antibody (Center) (RB02082) in HeLa cell line lysates (35ug/lane). MAGEA1 (arrow) was detected using the purified Pab.

Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.



Formalin-fixed and paraffin-embedded human lung carcinoma tissue reacted with MAGEA1 Antibody (Center) (Cat.#AP6163a), which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.

Citations

- [Expressions of melanoma-associated antigen A1 as a prognostic factor in Chinese patients with resectable oesophageal squamous cell carcinoma.](#)

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.